Is high-dose intravenous fosfomycin safe for the treatment of patients prone to heart failure?

Enferm Infecc Microbiol Clin. 2015 Apr;33(4):294. doi: 10.1016/j.eimc.2014.07.005. Epub 2014 Oct 23.

Authors

Irene Cañamares-Orbis¹, José Tiago Silva², Francisco López-Medrano², Jose Maria Aguado²

Affiliations

¹ Pharmacy Department, University Hospital 12 Octubre, Avda. Cordoba s/n., 28041 Madrid, Spain. Electronic address: [email protected].
² Infectious Diseases Unit, University Hospital 12 Octubre, Madrid, Spain.

PMID: 25444038
DOI: 10.1016/j.eimc.2014.07.005

No abstract available

Publication types

Letter

MeSH terms

Aged, 80 and over
Anti-Bacterial Agents / administration & dosage
Anti-Bacterial Agents / adverse effects*
Anti-Bacterial Agents / therapeutic use
Aortic Valve Insufficiency / etiology
Atrial Fibrillation / complications
Daptomycin / therapeutic use
Dose-Response Relationship, Drug
Drug Therapy, Combination
Dyspnea / etiology
Endocarditis, Bacterial / complications
Endocarditis, Bacterial / drug therapy*
Female
Fosfomycin / administration & dosage
Fosfomycin / adverse effects*
Fosfomycin / therapeutic use
Heart Failure / chemically induced*
Hepatitis C, Chronic / complications
Humans
Prosthesis-Related Infections / drug therapy*
Sodium / administration & dosage
Sodium / adverse effects*
Staphylococcal Infections / drug therapy*

Substances

Anti-Bacterial Agents
Fosfomycin
Sodium
Daptomycin